Introduction
DNA methylation arrays greatly improve diagnostic precision and reliability, and are highly effective for the discovery of new tumor types [
1]. This is particularly true of central nervous system (CNS) embryonal tumors, a tumor class comprising a growing list of subgroups largely refined by epigenetic studies [
2]. These tumors are high-grade malignancies composed of primitive neuroepithelial cells, predominantly seen in childhood. The 2021 update to the World Health Organization (WHO) classification of CNS tumors saw the incorporation of several new CNS embryonal tumors subtypes, including: cribriform neuroepithelial tumor; CNS neuroblastoma,
FOXR2-activated; and CNS tumor with BCOR internal tandem duplication [
3].
Recently, two cases of CNS embryonal tumors harboring a
BRD4::LEUTX fusion were described [
4,
5]. One of these reports characterized the fusion in a large series of pediatric cancers [
5], while the other incorporated detailed clinical and pathological data, including methylome analysis matching to the novel Heidelberg version 12 classifier class “CNS embryonal tumor with
BRD4::LEUTX fusion” [
4]. Three additional cases also exist in the literature, which while not specifically described as such, were initially presented before the version 12 of the Heidelberg classifier was available to interrogate this provisional tumor type [
6‐
8]. In addition to these 5 cases, we describe 4 additional unpublished new cases of CNS tumors with
BRD4::LEUTX fusions, thereby expanding the limited characterization available for this tumor type to date.
Discussion
We report on a series of cases that show fusions involving
BRD4 and
LEUTX and match to the corresponding DKFZ-Heidelberg class describing this tumor type. Patients with these tumors are young, and the tumors show features of an embryonal neoplasm. These are rare tumors, but important to recognize, as they are genomically and epigenetically distinct from other CNS embryonal neoplasms. The
BRD4 gene plays a crucial role in transcriptional regulation and in development, it maintains stem cell pluripotency. Dysregulation of
BRD4 has been linked to various cancers, where it contributes to cell proliferation and tumor progression. Known fusions include the
BRD4::NUT fusion in NUT midline carcinoma [
17‐
19]. The
LEUTX gene (also known as Leucine Twenty Homeobox), is a homeobox gene with a role in embryonic development and in regulating early cell differentiation. Fusions in this gene also play a role in cancer, including in primary CNS sarcomas involving
CIC::LEUTX fusions [
20,
21], and of interest,
CIC::LEUTX fusions have recently been described in a novel glioneuronal tumor [
22].
Interestingly, all fusions had the same breakpoint in
LEUTX (exon 2; Fig.
2), which has previously been shown to lead to increased
LEUTX expression, otherwise present almost exclusively in non-neoplastic embryonal tissues [
16]. In three cases (#1, #3, and #4) the fusion transcript involving exon 11 of
BRD4 was identical to the one reported in an embryonal CNS tumor and a pediatric sarcoma with epithelioid features [
16]. The
BRD4 portion encoded by this transcript (in the estimated chimeric protein) has the same length and structure of a shorter isoform of the protein (BRD4-S) previously shown to be implicated in breast cancer growth and metastasis, potentially mimicking BRD4-S pro-oncogenic activity [
23,
24]. In case #2 and case #5 [
4], the
BRD4 component of the fusion transcript is longer (Table
1) but still does not include a positive transcription elongation factor b (P-TEFb) interaction domain, and the intrinsically disordered region (IDR) is shorter than in the long
BRD4 isoform (BRD4-L); the latter being associated with tumor suppressor activity [
25]. Of note, small-molecule BRD4 inhibitors and BRD4 degraders have shown promising results in preliminary studies in hematological and solid malignancies, and may represent a future therapeutic avenue for these aggressive tumors [
26].
Despite molecular similarity, morphological and immunohistochemical features do not appear to overlap between
BRD4::LEUTX fused CNS tumors and the single case of sarcoma with epithelioid features reported in the literature [
16], nor with one case of possible alveolar rhabdomyosarcoma also reported to harbor a
BRD4::LEUTX fusion [
27]. DNA methylation profiling of these sarcomas would be helpful to determine how epigenetically similar these diseases are to CNS embryonal tumors with the same fusion. Indeed, pathological features can overlap between embryonal tumor subtypes, particularly those with
BRD4::LEUTX fusions and
FOXR2-activated neuroblastomas; most notably the small poorly differentiated cells, abundant necrosis, and co-expression of immunomarkers synaptophysin and OLIG2. A further overlapping feature with
FOXR2-activated neuroblastoma is the gain of chr1q, which was found in two of our cases, and positivity for SOX10 seen in one of two cases tested [
7].
Depending on tumor location, other embryonal tumors such as medulloblastoma and pineoblastoma should be considered in the differential diagnosis for this tumor type. Well-formed rosettes were not seen in all cases in our series, but these are not necessarily observed in medulloblastomas and pineoblastomas. OLIG2 positivity would be unexpected in both tumors. Embryonal tumors with multilayered rosettes (ETMRs) which otherwise lack rosettes, a medulloepithelioma component, and neurocytic/neuropil-rich areas could also resemble embryonal tumors with
BRD4::LEUTX fusions, but they are generally negative for OLIG2 and positive for LIN28A. The recently described entity “CNS tumor with
PLAGL amplification” (particularly
PLAGL2 in infants and toddlers) also shows overlapping embryonal features with the tumors in this series [
28], nonetheless with a different immune-profile—OLIG2 being mostly negative, and synaptophysin being patchy and weak. Interestingly, reduction of H3k27me3 was detected in three cases, one in the tectal plate/third ventricle, and two located in peduncular/thalamic region, with complete loss of expression reported in one case in the parietal lobe [
3]. Nonetheless, these potential mimics of diffuse midline glioma (DMG), K27-altered tumors seem to be more circumscribed, without evidence of diffuse infiltration both radiologically and histologically. Also, most DMG show glial morphology, and most do not exhibit extensive positivity for synaptophysin. Moreover, the loss of H3k27me3 can be observed in different CNS tumors and is caused by various mechanisms, generally leading to loss of transcriptional repression [
29].
Our sample size is small, but initial clinical investigation showed that these were clinically aggressive, and the evolution of patient #5, who died of disease progression shortly after surgery, is in line with these features. Nevertheless, two patients who underwent stereotactic biopsies showed tumor reduction with chemotherapy, permitting subsequent gross total resection, though one of these relapsed. Two patients were alive without evidence of recurrence or progression after gross total resection and chemotherapy 16 and 33 months after initial diagnosis, one of them already one year off-therapy, suggesting that at least some of these tumors may benefit from chemotherapy.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.